Incyte (INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies – evaluating the safety and efficacy of twice-daily ruxolitinib cream 1.5%, a topical JAK1/2 inhibitor, in adult patients with prurigo nodularis. The positive TRuE-PN1 data were presented as a late-breaking oral presentation at the 2025 American Academy of Dermatology, AAD, Annual Meeting, being held March 7-11, 2025, in Orlando. The TRuE-PN1 study met its primary endpoint demonstrating that significantly more PN patients who applied ruxolitinib cream 1.5% versus vehicle control achieved a greater than or equal to4-point improvement from baseline in Worst-Itch Numeric Rating Scale at Week 12. Significant itch improvements were observed with ruxolitinib cream 1.5% versus vehicle control at Day 7, with numerical improvements versus vehicle control reported at earlier timepoints. Additionally, the TRuE-PN1 study met all key secondary endpoints, including:
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Moody’s, Chubb, Incyte, Five9, CME: Insider Sales Surge
- Incyte: Genesis Therapeutics to receive $30M upfront in AI collaboration
- Incyte’s Strong Q4 Performance and Promising Growth Outlook Earns ‘Buy’ Rating
- Incyte’s Earnings Call: Robust Growth Amid Challenges
- Incyte price target raised to $88 from $86 at TD Cowen